CCCC Logo

C4 Therapeutics Inc (CCCC) Stock Forecast & Price Prediction

Live CCCC Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$3.37

-0.18 (-5.07%)

12 Month Price Forecast For CCCC

$3.37
Current Price
$237.88M
Market Cap
9 Ratings
Buy 6
Hold 3
Sell 0
Wall St Analyst Ratings

Distance to CCCC Price Forecasts

+1,383.7%
To High Target of $50.00
+285.8%
To Median Target of $13.00
+18.7%
To Low Target of $4.00

CCCC Price Momentum

-0.9%
1 Week Change
-7.9%
1 Month Change
-45.2%
1 Year Change
-6.4%
Year-to-Date Change
-71.6%
From 52W High of $11.88
+3.7%
From 52W Low of $3.25

๐Ÿค” Considering C4 Therapeutics (CCCC)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 5:04 AM UTC

CCCC Analyst Ratings & Price Targets

Based on our analysis of 11 Wall Street analysts, CCCC has a bullish consensus with a median price target of $13.00 (ranging from $4.00 to $50.00). Currently trading at $3.37, the median forecast implies a 285.8% upside. This outlook is supported by 6 Buy, 3 Hold, and 0 Sell ratings.

Conversely, the most conservative target is provided by Sudan Loganathan at Stephens & Co., suggesting a 18.7% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CCCC Analyst Consensus

6
Buy
3
Hold
0
Sell

CCCC Price Target Range

Low
$4.00
Average
$13.00
High
$50.00
Current: $3.37

Latest CCCC Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CCCC.

Date Firm Analyst Rating Change Price Target
Dec 19, 2024 Wells Fargo Derek Archila Overweight Upgrade $12.00
Nov 18, 2024 Stephens & Co. Sudan Loganathan Equal-Weight Initiates $4.00
Aug 6, 2024 BMO Capital Etzer Darout Outperform Reiterates $20.00
May 9, 2024 Stifel Bradley Canino Buy Maintains $14.00
May 9, 2024 Wells Fargo Derek Archila Equal-Weight Maintains $8.00
Feb 26, 2024 Morgan Stanley Terence Flynn Equal-Weight Maintains $8.00
Feb 23, 2024 Stifel Bradley Canino Buy Reiterates $13.00
Jan 29, 2024 JP Morgan Eric Joseph Neutral Upgrade $6.00
Dec 13, 2023 Stifel Bradley Canino Buy Upgrade $12.00
Nov 6, 2023 Morgan Stanley Terence Flynn Equal-Weight Upgrade $1.00
Nov 3, 2023 BMO Capital Etzer Darout Outperform Maintains $16.00
Nov 2, 2023 HC Wainwright & Co. Andrew Fein Buy Maintains $7.00
Oct 9, 2023 B of A Securities Chi Fong Neutral Maintains $2.00
Aug 9, 2023 HC Wainwright & Co. Andrew Fein Buy Maintains $17.00
May 30, 2023 Evercore ISI Group Gavin Clark-Gartner Outperform Maintains $10.00
May 12, 2023 Morgan Stanley Terence Flynn Underweight Maintains $3.00
May 8, 2023 HC Wainwright & Co. Andrew Fein Buy Maintains $25.00
Mar 28, 2023 B of A Securities Chi Fong Neutral Maintains $5.00
Feb 27, 2023 Morgan Stanley Terence Flynn Underweight Maintains $5.00
Feb 24, 2023 JP Morgan Eric Joseph Underweight Downgrade $5.00

Stocks Similar to C4 Therapeutics Inc

The following stocks are similar to C4 Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

C4 Therapeutics Inc (CCCC) Financial Data

C4 Therapeutics Inc has a market capitalization of $237.88M with a P/E ratio of -1.3x. The company generates $33.67M in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is +38.7% quarter-over-quarter, while maintaining an operating margin of -183.9% and return on equity of -46.0%.

Valuation Metrics

Market Cap $237.88M
Enterprise Value $62.04M
P/E Ratio -1.3x
PEG Ratio -2.0x
Price/Sales 7.1x

Growth & Margins

Revenue Growth (YoY) +38.7%
Gross Margin N/A
Operating Margin -183.9%
Net Margin 0.0%
EPS Growth +38.7%

Financial Health

Cash/Price Ratio +107.5%
Current Ratio 6.3x
Debt/Equity 27.7x
ROE -46.0%
ROA -20.6%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

C4 Therapeutics Inc logo

C4 Therapeutics Inc (CCCC) Company Overview

About C4 Therapeutics Inc

What They Do

Develops therapies to degrade disease-causing proteins.

Business Model

C4 Therapeutics focuses on creating and advancing innovative therapeutic candidates that target and degrade specific disease-causing proteins, primarily for cancer and neurodegenerative conditions. The company generates revenue through strategic collaborations and partnerships with major pharmaceutical companies, which may include milestone payments and royalties based on product commercialization.

Additional Information

C4's lead candidate, CFT7455, is currently in Phase 1/2 trials for multiple hematological malignancies, while other candidates like CFT1946 and CFT8919 are also under development for various cancers. The company, founded in 2015 and based in Watertown, Massachusetts, has established significant partnerships with industry leaders, enhancing its research and development capabilities.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

145

CEO

Mr. Andrew J. Hirsch M.B.A.

Country

United States

IPO Year

2020

C4 Therapeutics Inc (CCCC) Latest News & Analysis

CCCC stock latest news image
Quick Summary

C4 Therapeutics (CCCC) shows a hammer chart pattern suggesting potential support after recent declines, alongside positive earnings estimate revisions, indicating a possible trend reversal.

Why It Matters

The hammer chart pattern suggests potential price recovery for C4 Therapeutics, while rising earnings estimates indicate improved investor sentiment, possibly leading to a trend reversal.

Source: Zacks Investment Research
Market Sentiment: Positive
CCCC stock latest news image
Quick Summary

Cemsidomide combined with dexamethasone in Multiple Myeloma trials achieved a 36% overall response rate and a 45% clinical benefit rate, with responses noted at all dose levels tested.

Why It Matters

The promising response rates for Cemsidomide in treating Multiple Myeloma may indicate strong market potential, attracting investor interest in biotech firms developing similar therapies.

Source: GlobeNewsWire
Market Sentiment: Neutral
CCCC stock latest news image
Quick Summary

C4 Therapeutics appointed Steve Hoerter to its Board of Directors, enhancing leadership with over 30 years of oncology experience to drive pipeline progress.

Why It Matters

The appointment of Steve Hoerter enhances C4T's leadership in oncology, signaling potential growth and success in its drug pipeline, which could positively impact stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
CCCC stock latest news image
Quick Summary

C4 Therapeutics reported a quarterly loss of $0.35 per share, better than the expected loss of $0.40, and an improvement from a loss of $0.55 per share a year ago.

Why It Matters

C4 Therapeutics' smaller-than-expected loss indicates improving financial performance, which may boost investor confidence and positively impact the stock price.

Source: Zacks Investment Research
Market Sentiment: Negative
CCCC stock latest news image
Quick Summary

C4 Therapeutics (Nasdaq: CCCC) granted 345,600 non-qualified stock options to a new employee on October 28, 2024, as an inducement for employment, per Nasdaq rules.

Why It Matters

C4 Therapeutics' stock options grant indicates potential growth and talent acquisition, which could enhance its innovation pipeline and market position, influencing investor sentiment and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
CCCC stock latest news image
Quick Summary

Mahaney joins with over 25 years of experience in pharmaceuticals and biotech, focusing on drug discovery and enhancing clinical portfolios.

Why It Matters

Mahaney's extensive experience in drug discovery and clinical portfolios may enhance the company's innovation pipeline, potentially leading to successful product launches and increased market value.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About CCCC Stock

What is C4 Therapeutics Inc's (CCCC) stock forecast for 2025?

Based on our analysis of 11 Wall Street analysts, C4 Therapeutics Inc (CCCC) has a median price target of $13.00. The highest price target is $50.00 and the lowest is $4.00.

Is CCCC stock a good investment in 2025?

According to current analyst ratings, CCCC has 6 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.37. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CCCC stock?

Wall Street analysts predict CCCC stock could reach $13.00 in the next 12 months. This represents a 285.8% increase from the current price of $3.37. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is C4 Therapeutics Inc's business model?

C4 Therapeutics focuses on creating and advancing innovative therapeutic candidates that target and degrade specific disease-causing proteins, primarily for cancer and neurodegenerative conditions. The company generates revenue through strategic collaborations and partnerships with major pharmaceutical companies, which may include milestone payments and royalties based on product commercialization.

What is the highest forecasted price for CCCC C4 Therapeutics Inc?

The highest price target for CCCC is $50.00 from at , which represents a 1,383.7% increase from the current price of $3.37.

What is the lowest forecasted price for CCCC C4 Therapeutics Inc?

The lowest price target for CCCC is $4.00 from Sudan Loganathan at Stephens & Co., which represents a 18.7% increase from the current price of $3.37.

What is the overall CCCC consensus from analysts for C4 Therapeutics Inc?

The overall analyst consensus for CCCC is bullish. Out of 11 Wall Street analysts, 6 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $13.00.

How accurate are CCCC stock price projections?

Stock price projections, including those for C4 Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.